Market Trends of Carglumic Acid Industry
This section covers the major market trends shaping the Carglumic Acid Market according to our research experts:
Dispersible Tablets Segment is Expected to Hold a Significant Market Share
The dispersible tablets disintegrate quickly in water or disperse immediately in the mouth. The tablets can be administered quickly and help patients such as pediatrics, stroke patients, and elderly people who have difficulty swallowing other dosage forms. Thus, the demand for these dosage forms is increasing, and the segment is expected to witness growth.
According to an article published by Pharmaoffer in August 2022, people with high levels of ammonia in their blood are given a tablet called carbaglu. This is the first and only drug approved by the FDA to treat acute hyperammonemia caused by propionic acidemia (PA) or methylmalonic acidemia (MMA).The same source above also stated that the dosage per kilogram of body mass varies daily from 100 mg to 250 mg, depending on how severe the problem is. Because the dosage form is good for both young and old patients, the drug is becoming more popular.As a result, the carbaglu dispersible tablet is expected to boost segmental growth.
Segmental growth is likely to be driven by the growing number of people with NAGS syndrome, cancer, and metabolic disorders like hepatic encephalopathy, Reye's syndrome, and cirrhosis around the world. Orphanet's update from November 2022 says that hyperammonemia caused by N-acetylglutamate synthase deficiency is a rare autosomal recessive disorder of urea cycle metabolism that makes it hard to get rid of ammonia and make arginine. It affects less than 1 out of every 1,000,000 people.The disease's presence in the population creates a need for new ways to treat it, which in turn creates more opportunities for dispersible tablets.Thus, it is expected to drive segmental growth.
As a result, during the forecast period, the aforementioned factors are likely to be the main drivers of the segment's growth.
North America is Anticipated to Grow Significantly Over the Forecast Period
North America is expected to hold the largest share of the carglumic acid market throughout the forecast period. Several factors such as increasing incidences of various cancers like breast cancer, lung cancer, and hyperammonemia in North America led to high demand for carglumic acid in the region. Also, key pharmaceutical companies investing in research activities to develop novel products to treat cancers using carglumic acid are creating opportunities for the market to be studied. In addition, regulatory bodies such as the USFDA create awareness about carglumic acid products, along with their dosage and use in the region. Thus, the availability of such regulatory bodies ensures the safety of the products and contributes to the market's growth.
According to a 2022 update by National Organization for Rare Disorders (NORD), hepatic encephalopathy is most often associated with cirrhosis, which is estimated to affect nearly 5.5 million people in the United States, and nearly 70% of individuals with cirrhosis may develop symptoms of hepatic encephalopathy in 2022. As carglumic acid is used for the treatment of severe hyperammonemia that occurs due to a deficiency of hepatic NAGS the demand for carglumic acid is expected to grow for treatment. This is expected to create a huge demand and opportunities for carglumic acid, fueling the market growth in the region.
Further, as per an article published in March 2022 in NCBI, urea cycle disorders is one of the causes of hyperammonemia and a gross estimate of the incidence of urea cycle disorders is 1 in 250,000 live births in the United States. Thus, the burden of hyperammonemia creates demand for the usage of carglumic acid. This is expected to accelerate the market in the country.
Therefore, the above-mentioned factors are expected to drive the market in the region during the forecast period.
